ImmuPharma (GB:IMM) has released an update.
ImmuPharma PLC, a drug discovery and development company, reports a reduced annual loss of £2.9m and progress in its late-stage clinical assets, including a Phase 3 study for its leading drug candidate P140 in SLE, with a new dose strategy and insights into its mechanism of action. The company also notes positive FDA guidance for a Phase 2/3 study in CIDP, active discussions with potential partners, and successful fundraising efforts totaling £1.48 million.
For further insights into GB:IMM stock, check out TipRanks’ Stock Analysis page.
